Description
Inhibits platelet aggregation by antagonizing thromboxane A. Prostaglandin I2 Sodium Salt, MP Biomedicals is a short-lived product of the cyclooxygenase pathway in vascular endothelial cells. Prostacyclin therapy improves hemodynamics in pulmonary arteria
Prostaglandin I2 Sodium Salt is a potent fibrinolytic that antagonizes thromboxane A. It relaxes vascular smooth muscle and induces vasodilation. It also increases cyclic AMP concentration in human platelets (IC50 for human platelet aggregation is about 0.001 nM). Prostacyclin is vasoprotective, protecting arterial walls from injury-induced lesions and cytoprotective in the liver and gastrointestinal tract.
Prostaglandin I2 sodium salt stimulates platelet adenylyl cyclase. Nitric oxide is also produced in vascular endothelium, where it inhibits platelet aggregation, regulates inducible cyclooxygenase production, and may work synergistically with prostacyclin to attenuate the thrombotic process.
| CAS | 61849-14-7 |
| Molecular Formula | C20H31NaO5 |
| Molecular Weight (g/mol) | 374.453 |
| InChI Key | LMHIPJMTZHDKEW-HIHHSTLZSA-M |
| PubChem CID | 133687047 |
| IUPAC Name | sodium;(5Z)-5-[(3aS,4S,5S,6aR)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate |
| SMILES | CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)[O-])O2)O)O.[Na+] |
